Israel-based multi-country operator IM Cannabis (CSE: IMCC) (NASDAQ: IMCC) announced this week that the company has signed a multi-year deal with Canadian licensed producer The FLOWR Corporation (OTC: FLWPF), under which the latter will provide its ultra-premium cannabis strains to IM Cannabis for distribution and sale in Israel under the IMC brand.
On the three-year deal, Oren Shuster, CEO of IM Cannabis said in a statement to Benzinga that, “As the Israeli medical cannabis market continues to expand, demand from patients for premium high-THC products increases. The agreement with FLOWR is another cornerstone in IM Cannabis’ growth strategy to enhance its product portfolio in the local market with a new category of indoor ultra-premium offerings.
“With the local market expected to boom thanks to the impending legalization supported by the upcoming new government, we will continue to collaborate and partner with leading global cultivators to ensure patients who trust our brand and rely on our products, have access to the highest quality medical cannabis available,” Shuster continued.
IM Cannabis says the first shipment of the FLOWR strains is expected to be available to Israeli patients during the second half of 2021 and distributed through licensed pharmacies, including IM Cannabis’ online pharmacy and distribution network it acquired recently from Panaxia.
Flowr is an established leader in Canada’s premium dry flower market. This new partnership with Flowr strengthens and further contributes to IMC’s new indoor ultra-premium product category under the IMC brand.
Disclaimer: We have no position in any of the companies mentioned and have not been compensated for this article.
